Sino Biopharmaceutical Limited Stock price

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:23 2024-03-19 am EDT 5-day change 1st Jan Change
3.15 HKD -3.67% Intraday chart for Sino Biopharmaceutical Limited -1.25% -9.22%

Financials

Sales 2023 * 30.22B 4.2B 32.84B Sales 2024 * 33.2B 4.61B 36.07B Capitalization 55.38B 7.69B 60.18B
Net income 2023 * 2.95B 410M 3.2B Net income 2024 * 3.36B 467M 3.65B EV / Sales 2023 * 1.72 x
Net cash position 2023 * 3.31B 459M 3.59B Net cash position 2024 * 6.33B 879M 6.88B EV / Sales 2024 * 1.48 x
P/E ratio 2023 *
19.9 x
P/E ratio 2024 *
17.4 x
Employees 26,079
Yield 2023 *
1.95%
Yield 2024 *
2.23%
Free-Float 51.86%
More Fundamentals * Assessed data
Dynamic Chart
Sino Biopharmaceutical's Developing Two Drugs for MASH MT
Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy MT
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" CI
Sino Biopharmaceutical to Present Cancer Drug Phase II Trial Findings at 2024 AACR MT
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet CI
Hong Kong Shares Slump Amid Chinese Growth Concerns MT
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart CI
Sino Biopharmaceutical's Anti-Cancer Drug Under Priority Review in China MT
Sino Biopharm Units Sell 67% Stake in Pharmaceutical Company MT
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 million RE
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical Co., Ltd from Sino Biopharmaceutical Limited for CNY 1.8 billion. CI
Sino Biopharmaceutical Files for Chinese Launch of Obeticholic Acid Tablets MT
China Outlook, Profit-Taking Roil Asian Stock Markets MT
Sino Biopharmaceutical Repurchases Over 78 Million Shares Under Buyback Plan MT
Sino Biopharm's Lung Cancer Drug Added to China's Priority List for Evaluation MT
More news
1 day-3.67%
1 week-1.25%
Current month+0.64%
1 month+1.61%
3 months+0.96%
6 months+7.14%
Current year-9.22%
More quotes
1 week
3.13
Extreme 3.13
3.46
1 month
2.89
Extreme 2.89
3.46
Current year
2.71
Extreme 2.71
3.49
1 year
2.57
Extreme 2.57
4.73
3 years
2.57
Extreme 2.57
9.69
5 years
2.57
Extreme 2.57
11.24
10 years
1.70
Extreme 1.6978
11.24
More quotes
Managers TitleAgeSince
Chief Executive Officer 29 19-10-22
Founder 72 00-02-01
Director of Finance/CFO 53 -
Members of the board TitleAgeSince
Founder 72 00-02-01
Director/Board Member 60 04-12-31
Director/Board Member 54 95-07-31
More insiders
Date Price Change Volume
24-03-19 3.15 -3.67% 58 503 590
24-03-18 3.27 +0.31% 28,235,230
24-03-15 3.26 -1.21% 59,088,670
24-03-14 3.3 +3.12% 109,936,100
24-03-13 3.2 +0.31% 38,008,600

Delayed Quote Hong Kong S.E., March 19, 2024 at 04:08 am EDT

More quotes
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
3.01 CNY
Average target price
4.528 CNY
Spread / Average Target
+50.43%
Consensus
  1. Stock
  2. Equities
  3. Stock Sino Biopharmaceutical Limited - Hong Kong S.E.